Home
Products
R & D
News
Contact
Investor Relations
Profile
Untitled Document
( 3/18/2004 8:57:34 AM )
Amazon Biotech Inc. Announces Change of Stock Symbol To AMZB
NEW YORK, March 18, 2004 (PRIMEZONE) -- Amazon Biotech Inc. (OTC BB:AMZB.OB - News) announced that it has changed its stock symbol from AYST to AMZB, effective March 15, 2004. Amazon Biotech(AMZB) did a reverse merger into Asyst Corporation, formerly traded under the symbol of AYSC. Amazon Biotech acquired an immunomodulator drug, now named AMZ 0026, which has been issued an Investigational New Drug (IND) number and has been approved for Phase I/II clinical studies for HIV by the FDA. The company expects to begin Phase II of the clinical studies this year About Amazon Biotech Amazon Biotech, Corp. is a newly established pharmaceutical company currently producing AMZ 0026 and a revolutionary, topical natural hair-growth product. The company intends to initiate Phase I/II clinical studies of AMZ 0026 in the near future, with an eventual goal of a joint venture with a major pharmaceutical company in Phase III trials. During 2004, Amazon Biotech plans to conduct a small double blind study on its hair growth product. The company also plans to market the hair growth product through a Fortune 1000 company. Additional information on Amazon Biotech may be found at http://www.amazonbiotech.com FORWARD LOOKING STATEMENTS: ``Safe-Harbor'' Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words ``believes,'' ``expects,'' ``anticipates,'' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof. Contact: LC Group 404-261-1196
Next
All Rights Reserved Amazon BioTech
